Correction to: How is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural Enhancement.

MLA

Severin, Thomas, et al. “Correction to: How Is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural Enhancement.” Therapeutic Innovation & Regulatory Science, vol. 54, no. 5, Sept. 2020, p. 1085. EBSCOhost, https://doi.org/10.1007/s43441-020-00152-0.

APA

Severin, T., Corriol-Rohou, S., Bucci-Rechtweg, C., an Haack, K., Fuerst-Recktenwald, S., Lepola, P., Norjavaara, E., Dehlinger-Kremer, M., Haertter, S., & Cheung, S. Y. A. (2020). Correction to: How is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural Enhancement. Therapeutic Innovation & Regulatory Science, 54(5), 1085. https://doi.org/10.1007/s43441-020-00152-0

Chicago

Severin, Thomas, Solange Corriol-Rohou, Christina Bucci-Rechtweg, Kristina an Haack, Sabine Fuerst-Recktenwald, Pirkko Lepola, Ensio Norjavaara, Martine Dehlinger-Kremer, Sebastian Haertter, and S. Y. Amy Cheung. 2020. “Correction to: How Is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural Enhancement.” Therapeutic Innovation & Regulatory Science 54 (5): 1085. doi:10.1007/s43441-020-00152-0.